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Abstract
Background: Estrogen is an established enhancer of breast cancer development, but less is known on its effect on local
progression or metastasis. We studied the effect of estrogen receptor recruitment on actin cytoskeleton remodeling and
breast cancer cell movement and invasion. Moreover, we characterized the signaling steps through which these actions are
enacted.
Methodology/Principal Findings: In estrogen receptor (ER) positive T47-D breast cancer cells ER activation with 17b-
estradiol induces rapid and dynamic actin cytoskeleton remodeling with the formation of specialized cell membrane
structures like ruffles and pseudopodia. These effects depend on the rapid recruitment of the actin-binding protein moesin.
Moesin activation by estradiol depends on the interaction of ERa with the G protein Ga13, which results in the recruitment
of the small GTPase RhoA and in the subsequent activation of its downstream effector Rho-associated kinase-2 (ROCK-2).
ROCK-2 is responsible for moesin phosphorylation. The Ga13/RhoA/ROCK/moesin cascade is necessary for the cytoskeletal
remodeling and for the enhancement of breast cancer cell horizontal migration and invasion of three-dimensional matrices
induced by estrogen. In addition, human samples of normal breast tissue, fibroadenomas and invasive ductal carcinomas
show that the expression of wild-type moesin as well as of its active form is deranged in cancers, with increased protein
amounts and a loss of association with the cell membrane.
Conclusions/Significance: These results provide an original mechanism through which estrogen can facilitate breast cancer
local and distant progression, identifying the extra-nuclear Ga13/RhoA/ROCK/moesin signaling cascade as a target of ERa in
breast cancer cells. This information helps to understand the effects of estrogen on breast cancer metastasis and may
provide new targets for therapeutic interventions.
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Introduction
One out of eight women develop breast cancer at some stage
throughout life [1]. Despite the recent improvements in survival
rates, many patients relapse, and the majority of these patients die
for disseminated metastatic disease, which supports the need for
new therapeutic strategies.
In the mammary gland, the sex steroid estrogen promotes breast
growth and development at puberty and during the menstrual cycle
and pregnancy [2]. In addition to these physiological effects,
estrogen plays a major role in the development and progression of
breast cancer. Prolonged exposure to estrogen, i.e. early menarche,
late menopause or postmenopausal hormone replacement therapy,
is associated with a greater risk of developing breast cancer [3].
Estrogen promotes breast cancer proliferation through a number of
established pathways [4]. On the contrary, the effects of estradiol on
tumor cell motility and invasion are poorly understood.
Cell migration is required for cancer cell spread, invasion and
metastasis and it is achieved through a dynamic remodeling of
filamentous actin and of focal adhesion sites [5]. This process leads
to rapid changes of cell membrane morphology, with the
formation of specialized structures linked to cell movement such
as pseudopodia and ruffles [6]. Estrogen administration to breast
cancer cells is associated with estrogen receptor-a (ERa)
membrane translocation and with the rapid formation of such
specialized cell membrane structures [7]. Similar effects are found
in human endothelial cells, where estrogen alters the cytoskeleton
and increases cell migration through the activation of the actin
binding protein, moesin [8].
Moesin belongs to the ezrin-radixin-moesin (ERM) family of
actin-binding proteins [9]. By interacting with actin, activated
ERMs induce actin de-polymerization and re-assembly toward the
cell membrane edge, supporting the formation of cortical actin
complexes [10]. These complexes help the formation of molecular
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bridges between the actin cytoskeleton, integrins and focal
adhesion complexes within ruffles and pseudopodia and are
critical for cell movement [6].
Ezrin, another member of the ezrin/radixin/moesin (ERM)
family, is over-expressed in highly aggressive sarcomas [11,12], as
well as in breast cancer, being associated with higher metastasis
rate [13]. In addition, ezrin expression is induced by estrogens in
ovarian cancer cells [14] suggesting that ERM proteins might have
important functions in cancer progression and/or metastasis.
In this paper we study the effects of estradiol on the migration
and invasion of ER+ or ER2 breast cancer cells and we relate
these observations to actin remodeling and to the activation of
moesin, characterizing the signaling steps involved in these actions.
In addition, we study the expression and sub-cellular localization
of wild type and activated moesin in normal breast tissue, benign
breast disorders as well as in ER+ and ER2 invasive breast
carcinomas, highlighting the relationship with lymph node
metastasis.
Results
Estrogen receptor activation induces a rapid cytoskeletal
rearrangement and the development of specialized
membrane structures
To assess the potential effect of estrogen receptor (ER)
recruitment on breast cancer cell movement, we studied the
morphological changes of the actin cytoskeleton in ER+ T47-D
cells exposed to estradiol. Unstimulated cells displayed mainly
longitudinally-arranged actin fibres in the cytoplasm (Fig. 1A).
Recruitment of ER with 17b-estradiol (E2, 10 nM) resulted in a
rapid change in actin organization, with a remodeling of the fibres
toward the cell membrane edge (Fig. 1A). Plus, exposure to E2 was
associated with the formation of specialized membrane structures
linked to cell attachment to the extracellular matrix and to cell
movement, such as pseudopodia and membrane ruffles (Fig. 1A).
This phenomenon was time-dependent and transient, being
maximal after 15–20 minutes and then progressively reversing to
the basal arrangement between 30 and 60 minutes (Fig. 1A). The
remodeling of actin fibres and the morphological changes of the
membrane were quantified by assessing the intensity of the actin
fluorescence after conversion of the coloured pixels to greyscale
using the Leica QWin image analysis and processing software.
This analysis was performed selecting random boxes including the
extra- and intra-cellular space across the membrane, and the
linear intensity of the signal was spatially recorded. We sampled
five areas per each cell, and we repeated this on 30 different cells
per experimental condition. The upper graphs in Fig. 1A show the
analysis of sample boxes (displayed in white in the lower images)
used for the measurement. These measures allowed to identify the
thickness of the membrane, that is shown throughout the time-
course in Fig. 1B, as well as the mean6SD intensity of the actin
staining in the membrane, in the cytosol, as well as the
membrane/cytosol ratio (Fig. 1C).
Estrogen receptor recruitment turns into a rapid
activation of the actin-regulatory protein moesin
Activation of ER with E2 turned into a rapid increase of Thr558
phosphorylation (which corresponds to activation) [15,16] of the
actin-binding protein moesin (Fig. 2A). The activation of moesin
by E2 follows the same kinetics as actin rearrangement (Fig. 2A)
and was achieved through extra-nuclear pathways, as no changes
of cell immunoreactive moesin were found (Fig. 2A). In addition,
ERa and ERb were both expressed and their levels did not vary
throughout the time-course (Fig. 2A). In estrogen-receptor
negative MDA-MB-468 breast cancer cells moesin was constitu-
tively phosphorylated and exposure to estradiol did not alter this
activation any further, suggesting that this protein may be basally
over-active in these cells (Fig. 2B). As expected, nearly undetect-
able ERa and ERb expression was present in this cell line (Fig. 2B).
In T47-D breast cancer cells, the activation of moesin was
related to the concentration of E2 and was triggered by
physiological amounts of the steroid (Fig. 2C), whereas in MDA-
MB-468 cells no change in moesin phosphorylation was detected
throughout the range of estradiol concentrations (Fig. 2D).
Moesin is required for estrogen receptor-induced actin
remodeling
To assess whether moesin is required for the estrogen receptor-
dependent cytoskeletal rearrangement in T47-D cells, we silenced
moesin by transfection of specific antisense phosphorotioate
oligonucleotides (PONs) and observed the actions of E2 on actin
rearrangement. Moesin expression was significantly reduced when
T47-D breast cancer cells were transfected with antisense moesin
PONs for 72 h (Fig. 3A). In moesin-silenced cells, E2 failed to
induce a rapid actin reorganization as well as to to increase
membrane thickness or the actin membrane/cytosol ratio (Fig. 3B–
C). Furthermore, moesin-silenced cells did not develop specialized
membrane structures in the presence of E2 (Fig. 3B). As control,
E2 was fully effective in cells transfected with sense (inactive)
moesin PONs (Fig. 3B–C).
Estrogen activates moesin via ERa
Moesin activation induced by E2 in T47-D cells was prevented
by the addition of the pure ER antagonist ICI 182,780 (ICI, 1 mM)
(Fig. 4A), indicating that ER is required. Since ICI 182,780 is
reported to increase ER degradation, we checked for the levels of
ERa and b in our experimental conditions. After a total exposure
of 45 minutes to ICI (30 minutes of pre-treatment and 15 minutes
of combined E2 and ICI 182,780 administration), we found no
change in the levels of ERa or ERb. Indeed, in T47-D cells, we
find degradation of ERa in the presence of ICI 182,780 being
visible only at time-points later than 60 minutes (data not shown).
This is consistent with previous publications[17].
A similar ER-dependent activation of moesin was seen in MCF-
7 cells (Fig. 4B). On the contrary, ICI 182,780 had no inhibitory
effect on moesin phosphorylation in ER- MDA-MB-468 cells,
supporting the concept that in these cells the recruitment of this
protein does not require the presence of ERs (Fig. 4C).
To identify which ER isoform is required for the signaling of
estrogen to moesin, we treated T47-D cells with estradiol or with
the preferential ERa agonist 4,49,40-(4-propyl-[1H]-pyrazole-
1,3,5-triyl)trisphenol (PPT, 1nM) [18] or with the ERb agonist
2,3-bis(4-hydroxyphenil)-propionitrile (DPN, 1nM) [19]. Moesin
activation was detected only in the presence of estradiol or PPT,
suggesting that ERa supports the signaling to moesin, while ERb is
not required (Fig. 4D). In agreement, also MCF-7 cells treated
with PPT or DPN showed moesin activation in the presence of the
preferential ERa agonist (Fig. 4E).
Since the ER isoform selectivity of PPT and DPN is not absolute
(at higher concentrations they bind to some extent both ERa and
ERb), we silenced ERa in T47-D cells with targeted small
interfering RNAs (siRNAs). Transfection of ERa siRNAs resulted
in a clear reduction of ERa expression, along with a dramatic
decrease of the phosphorylation of moesin during exposure to
estrogen (Fig. 4F). This happened in the absence of modifications
of the expression of moesin or ERb (Fig. 4F), supporting the
hypothesis that ERa drives the signaling of estradiol to moesin.
ERa, Moesin and BC Movement
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ERa signals to moesin through a Ga13- and RhoA-
dependent signaling pathway
In the search for the signaling pathways through which ERa
leads to moesin activation in breast cancer cells, we used different
pharmacological inhibitors linked to ERa or moesin to treat
estrogen-receptor positive breast cancer cells. PD98059 (PD,
5 mM), an inhibitor of mitogen-activated protein kinases (MAPK)
and wortmannin (WM, 30 nM), an inhibitor of phosphatidylino-
sitol 3-OH kinase (PI3K), did not alter the estradiol-induced
moesin phosphorylation in T47-D (Fig. 5A) or MCF-7 cells
(Fig. 5B). As control, PD98059 and wortmannin were fully able to
block the estradiol-dependent activation of ERK 1/2 (Fig. 5C) or
of the PI3K effector Akt (Fig. 5D) in T47-D breast cancer cells.
Instead, the G protein inhibitor, pertussis toxin (PTX, 100 ng/
mL) significantly inhibited moesin phosphorylation induced by E2
(Fig. 5A and 5B). Moreover, the membrane-impermeable
estradiol-bovine serum albumin conjugate (E2-BSA, 10 nM)
triggered moesin activation similar to normal E2 (Fig. 5A and
5B). These findings suggest that a G protein-dependent, cell-
membrane initiated mechanism mediates the signaling of ERa to
moesin and to the actin cytoskeleton.
We previously showed that ERa is able to interact with the G
protein, Ga13, that controls the small GTPase RhoA and its
effector, Rho-associated kinase (ROCK) [8]. This signaling
cascade is implicated in the control of the cytoskeleton in human
vascular cells [8]. With co-immunoprecipitation assays we found
that in T47-D as well as in MCF-7 cells estradiol triggers a direct
association of ERa with Ga13 which is prevented by ICI 182,780
(Fig. 5E and 5F). In parallel, no co-immunoprecipitation of ERb
with Ga13 was found in either cell lines (Fig. 5E and 5F). Reverse
co-immunoprecipitations of ERa (Fig. 5G) and ERb (Fig. 5H)
followed by western analysis of Ga13 confirmed that Ga13 and
ERa (but not ERb) co-interact in a ligand-dependent fashion in
T47-D cells.
Figure 1. Recruitment of ER induces a dynamic remodeling of the actin cytoskeleton and of the cell membrane in T47-D breast
cancer cells. A) T47-D cells were treated for different times with E2 (10 nM). Actin fibers were stained with phalloidin linked to Texas Red (red
labeling) and nuclei were counterstained with DAPI (blue labeling). Immunofluorescent analysis reveals the dynamic modifications of actin fibers
through the time-course and the formation of specialized cell membrane structures. Green arrows indicate longitudinal fibers; light blue arrows
indicate membrane ruffles; yellow arrows indicate pseudopodia. Rectangles indicate the analyzed area which was demonstrated by the
corresponding upper graph. In the graph, the longitudinal axis represents the gray level and the horizontal axis indicates pixels. Yellow, red and blue
areas indicate the extracellular, plasma membrane and cytoplasmic fraction, respectively. B and C) Analytic results obtained by using Leica QWin
image analysis and processing software showing the mean thickness of the cell membrane as well as the intensity of actin staining in the cytoplasm,
membrane or extracellular compartment after treatment with E2 (10 nM) for different times. The results are derived from the sampling of five areas of
the cell membrane of thirty different random cells. The areas of minimum and maximum cell membrane thickness were always included. The results
are the mean6SD of the measurements. In C) * =p,0.05 vs. Basal condition (0 min).
doi:10.1371/journal.pone.0002238.g001
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With a double Immunofluorescent staining we were further able
to show that in the presence of estradiol Ga13 and ERa partially
co-localize in T47-D cells. In particular, spot-like double staining
of Ga13 and ERa was found on the cell membrane in the presence
of E2, which was antagonized by co-administration of ICI 182,780
(Fig. 6A).
By assaying RhoA GTP-binding activity, we found that RhoA is
activated in T47-D cells by rapid exposure to estradiol or to the
membrane-impermeable estradiol-BSA (Fig. 6B). RhoA activation
was prevented by ER antagonism with ICI 182,780 and by
interference with G proteins using PTX (Fig. 6B). The ERa-
selective agonist PPT was associated with a strong activation of
RhoA (Fig. 6B), while the ERb-preferential ligand, DPN, was also
found to increase RhoA GTP-binding, although to a lesser extent
(Fig. 6B).
To further test the requirement of Ga13 and RhoA for ERa-
induced moesin activation in T47-D breast cancer cells, we
performed transient transfections with Ga13 (Ga13 Q226L) or
RhoA (RhoA G14V) constitutively active mutated constructs or
with Ga13 (Ga13 Q226L/D294N) or RhoA (RhoA T19N)
dominant negative constructs (Fig. 6C). Breast cancer cells
transfected with constitutively active constructs showed an
over-active moesin phosphorylation that was independent of
estradiol (Fig. 6C). Instead, dominant negative Ga13 or RhoA
constructs significantly inhibited the estradiol-induced moesin
activation (Fig. 6C). Overall, these results show that Ga13 and
RhoA are implicated in the signaling of ERa to moesin in breast
cancer cells.
ERa and moesin phosphorylation: role of the Rho-
associated kinase (ROCK-2)
ROCK-2 phosphorylates moesin on Thr558 in different cell
types, leading to filamentous actin fibers polymerization [20]. Pre-
incubation of T47-D (Fig 7A) or MCF-7 (Fig 7B) breast cancer
cells with the specific Rho-kinase inhibitor, Y-27632 (Y-27632,
10 mM) prevented the activation of moesin by estradiol, implying
that ROCK-2 is required for estrogen signaling to moesin in ER+
breast cancer cells.
In agreement, ER activation resulted in increased ROCK-2
kinase activity in T47-D breast cancer cells (Fig. 7C). This was
suppressed by ICI 182,780, Y-27632 as well as by PTX (Fig. 7C),
indicating that ER recruitment turns into a G protein-dependent
ROCK-2 activation.
In addition, we previously showed that ERa is able to interact
with and directly activate ROCK-2 in human endothelial cells [8].
In T47-D breast cancer cells, an enhanced interaction between
ERa and ROCK-2 was found with co-immunoprecipitation
experiments in cells exposed to E2 (Fig. 7D–E). This protein-
protein interaction was blocked by ICI 182,780 but not by PTX
(Fig. 7D–E), suggesting that this may represent an additional
mechanism for ERa-dependent ROCK-2 recruitment. To check
whether the interaction with ERa turns ROCK-2 into an active
status, we performed kinase assays using ERa immunoprecipitates
(IPs) to target for Thr-phosphorylation the bait protein, myelin
basic protein (MBP). ERa immunoprecipitates obtained from
T47-D cells treated with estradiol induced MBP phosphorylation
(Fig. 7F). ICI 182,780 and the ROCK-2 inhibitor Y-27632
Figure 2. ER recruitment results in the activation of the actin-binding protein, moesin. Protein extracts from T47-D (A and C) and MDA-
MB-468 (B and D) breast cancer cells treated for different times with 10 nM E2 (A and B) or for 15 min with increasing concentrations of E2 (C and
D) were assayed with western analysis for their overall content of ERa and ERb , wild type moesin (moesin) or Thr558-phosphorylated moesin (P-
moesin).
doi:10.1371/journal.pone.0002238.g002
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counteracted this activation (Fig. 7F), confirming that ROCK-2
interacting with the ligand-engaged ERa is functionally activated.
Consistently with the previous results, PTX did not reduce the
activity of the ERa-associated-ROCK-2 (Fig. 7F), further
suggesting the presence of two separate pathways of activation of
ROCK-2 by ERa: one is G protein-dependent, while the second
relies on a direct ERa/ROCK-2 interaction, which is not sensitive
to PTX.
Ga13, RhoA and ROCK-2 are necessary for the ER-
dependent actin remodeling
To investigate whether Ga13, RhoA or ROCK-2 are required
for the ER-induced cytoskeletal remodeling, we studied the
architecture of actin fibers while transfecting T47-D cells with
the Ga13 or RhoA mutated constructs or in the presence of the
ROCK-2 inhibitor Y-27632. Both the Ga13 and RhoA constitu-
tively active constructs triggered a visible actin cytoskeleton
remodeling with generation of membrane protrusions, resulting
in enhanced interaction of T47-D cells with the extracellular
matrix and with nearby cells (Fig. 8A). Estradiol did not modify the
cytoskeletal structure any further in these cells (Fig. 8A). In
parallel, the dominant negative Ga13 and RhoA constructs
abrogated the modifications of actin and cell morphology induced
by estrogen (Fig. 8A). Moreover, the inhibition of ROCK with Y-
27632 prevented the effect of estradiol on cytoskeleton remodeling
(Fig. 8A). These changes were reflected in the measurements of the
mean membrane intensity and actin membrane/cytosol ratio
(Fig. 8B).
The changes in actin spatial organization were accompanied by
parallel modifications of the ratio between globular and fibrillar
actin. At baseline, actin fibers predominantly existed as monomers
(G-actin) (Fig. 8C). After treatment with E2 for 15 min, a visible
shift from G to F actin was seen (Fig. 8C), indicating that ER
recruitment is linked to polymerization of G-actin into F-actin.
Figure 3. Moesin is required for estrogen-induced cytoskeletal remodeling. A) T47-D cells were transiently transfected with antisense
(2 mM antisense MOESIN) moesin phosphorotioate oligonucleotides (PONs) for 0, 60 or 72 hours and moesin expression was assayed with western
analysis. B and C) T47-D cells were transiently transfected with vehicle or antisense (2 mM antisense MOESIN) or sense (2 mM sense MOESIN) moesin
phosphorotioate oligonucleotides (PONs) for 72 hours and then treated for 15 min with 10 nM E2. Moesin expression was checked by staining with a
specific Ab linked to FITC (green labeling). Actin fibers were stained with phalloidin-Texas Red (red labeling) and nuclei were counterstained with
DAPI (blue labeling). F) shows the analytic results obtained by using Leica QWin image analysis and processing software showing the mean thickness
of the cell membrane as well as the intensity of actin and moesin staining in the cytoplasm, membrane or extracellular compartment. The results are
derived from the sampling of five areas of the cell membrane of thirty different random cells. The areas of minimum and maximum cell membrane
thickness were always included. The results are the mean6SD of the measurements. * = p,0.05 vs. vehicle-transfected control.
doi:10.1371/journal.pone.0002238.g003
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The ER antagonist ICI 182,780, the G protein inhibitor, pertussis
toxin (PTX) and the Rho-kinase inhibitor Y-12732 largely
prevented the shift from G- to F-actin induced by estradiol
(Fig. 8C).
Recruitment of ER enhances breast cancer cell migration
and invasion through a G protein/ROCK/moesin pathway
To address the question of the relevance of the ERa/Ga13/
RhoA/ROCK/moesin signaling cascade on breast cancer cell
movement, we pretreated T47-D or MDA-MB-468 (ER-) breast
cancer cells with cytosine arabinoside (1-(b-D-arabino-furanosyl)-
cytosine hydrochloride-Ara-C, 100mM), an inhibitor of DNA
strand separation that prevents cell division (so to dissect the
actions of estrogen on movement from those on cell proliferation),
and we performed horizontal migration assays. Estradiol (E2, 10
nM) strongly enhanced the migration of T47-D cells (Fig. 9). This
was largely prevented by ICI 182,780, PTX and Y-27632, as well
as by moesin silencing with antisense oligonucleotides (Fig. 9). In
addition, the selective estrogen receptor modulator tamoxifen
(TAM, 10 nM) that is used in the adjuvant treatment of ER+
breast cancers, also reduced the migration of T47-D cells induced
by E2 while being ineffective on its own (Fig. 9).
In general, ER- MDA-MB-468 cells showed a stronger
tendency to migrate in comparison to T47-D cells and this was
not affected by E2, ICI, PTX or tamoxifen (Fig. 10). However, the
ROCK inhibitor, Y-27632, significantly decreased the migration
Figure 4. Estrogen signals to moesin via ERa. T47-D (A and D) , MCF-7 (B and E) or MDA-MB-468 (C) cells were treated for 15 minutes with
either E2 (10 nM), the preferential ERa agonist PPT (10 nM) or the preferential ERb agonist, DPN (10 nM), in the presence or absence of the ER
antagonist, ICI 182,780 (1 mM). Western analyses of ERa, ERb, wild-type moesin (moesin) or Thr558-phosphorylated moesin (P-moesin) were
performed. F) T47-D cells were transfected with siRNAs vs. ERa (siRNA ERa), with scrambled siRNAs or with vehicle, and protein analysis for ERa, ERb,
wild-type moesin (moesin) or Thr558-phosphorylated moesin (P-moesin) was performed on cell lysates after treatment for 15 min with vehicle or 10
nM E2.
doi:10.1371/journal.pone.0002238.g004
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of these cells (Fig. 10), suggesting that ROCK-2 may be overactive
in MDA-MB-468 cells, and that this may enhance their ability to
migrate.
To test the impact of the ER-dependent signaling to moesin on
breast cancer cell invasion we performed three-dimensional
invasion assays using matrigel. Ara-C-pretreated cells showed an
enhanced invasion of the matrix in the presence of E2 or E2-BSA
(Fig. 11). The effect of E2 was blocked by the ER-antagonist ICI
182,780, by PTX, by the ROCK-inhibitor Y-27632 as well as by
tamoxifen (Fig. 11). In addition, transfection of moesin antisense
PONs also resulted in impaired invasion in the presence of
estradiol (Fig. 11).
Moesin and P-moesin sub-cellular localization in normal
breast tissue, benign breast disease and invasive breast
cancer
To further characterize the biological role of moesin, we studied
the sub-cellular distribution of wild-type moesin and activated
moesin in normal and tumoral human breast tissues by
immunohistochemistry.
In normal human mammary ducts, staining for wild-type and
phosphorylated moesin was found on the apical surface of ductal
epithelial cells (Fig. 12), consistent with the usual localization in
polarized secretory cells [9]. In addition, both moesin and P-
moesin staining was present in occasional basal myo-epithelial
elements and in endothelial cells (Fig. 12). Similar to normal breast
tissue, in breast fibroadenomas (FAD) moesin and P-moesin were
prominently located at the cell membrane of epithelial elements
(Fig. 12), along with occasional stromal and myo-epithelial cells.
In addition, in order to characterize moesin and P-moesin
expression and distribution in invasive breast cancers, we stained
samples from human ductal carcinomas (tumor stage: pT1c–node
size between 1 and 2 cm-see Table 1) and we compared the
pattern of staining of ER positive or negative cancers, with or
without lymph node metastasis.
Different from normal breast tissues or fibroadenomas, invasive
ductal carcinomas showed a deranged moesin and P-moesin
cellular localization, with four main expression/distribution
patterns. Some cancers showed a weak, focal expression of moesin
(focal, less than 30% of the cells stain for moesin, Fig. 12). Other
cancers instead showed an intense staining for moesin, but some
had a strong expression of moesin at the cell membrane (Fig. 12),
while others showed a mixed membrane/cytoplasmic staining
(Fig. 12). Other tumors had instead a clear cytoplasmic moesin
staining, in the absence of membrane localization (Fig. 12).
There was no significant statistical difference in the association
of the type of staining with lymph node metastasis status in ER+ or
ER2 cancers. However, ER2 tumors showed a statistically
significant difference vs. ER+ cancers in wild-type moesin
Figure 5. ERa signals to moesin via Ga13 and RhoA. T47-D (A) or MCF-7 (B) cells were exposed for 15 min to 10 nM E2 or to E2 conjugated to
bovine serum albumin (E2-BSA; 10 nM), in the presence or absence of the ER antagonist ICI 182,720 (ICI; 1 mM), of the MAPK inhibitor PD98059 (PD;
5 mM), of the PI3 kinase inhibitor wortmannin (WM; 30 nM) or of the G protein inhibitor, PTX (100 ng/ml). ERa, ERb, wild-type moesin (moesin) or
Thr558-phosphorylated moesin (P-moesin) were assayed in cell extracts. C and D) T47-D cells were treated for 15 min with 10 nM E2, in the presence
or absence of the MAPK inhibitor PD98059 (PD; 5 mM) or of the PI3 kinase inhibitor wortmannin (WM; 30 nM). ERK 1/2 or Tyr204-phosphorylated-ERK
1/2, Akt or Ser473-phosphorylated Akt were assayed in cell extracts. T47-D cells E) or MCF-7 cells F) were treated for 15 min with 10 nM E2 in the
presence or absence of ICI 182,720 (ICI, 1 mM). Cell protein extracts were immunoprecipitated with an Ab. vs. Ga13 and the IPs were assayed for co-
immunoprecipitation of ERb or ERa. The membranes were re-blotted for Ga13 to show equal input. G and H) T47-D cell extracts were
immunoprecipitated with an Ab. vs. ERa (G) or vs. ERb (H) and the IPs were assayed for co-immunoprecipitation of Ga13. The membranes were re-
blotted for ER a or b to show equal imput.
doi:10.1371/journal.pone.0002238.g005
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localization, having consistently no membrane-only staining while
displaying a constant cytoplasmic moesin localization (Table 1). In
addition, although this was not significant, ER2 cancers with
lymph node metastasis tended to display more frequently a
cytoplasmic-only moesin staining, without any membrane locali-
zation (Table 1).
When P-moesin staining was studied, similar patterns of sub-
cellular distribution were found in invasive cancers (focal vs.
intense staining; membrane vs. membrane/cytoplasmic vs.
cytoplasmic, Fig. 12), but there was no significant association with
either ER or lymph node status (Table 1).
Discussion
Estrogens act as promoters of cell proliferation and movement
in different tissue types, including the breast [2]. This action is
particularly relevant in the presence of estrogen receptor positive
(ER+) breast cancers, that are driven to grow, invade and
metastasize by endogenous or exogenous estrogens [4,21]. For
these reasons, understanding the basis through which estrogens
drive cancer cells to interact with the extracellular environment to
enact movement and invasion heralds profound biological and
medical implications.
We here show that estrogen enhances horizontal migration and
invasion of three-dimensional matrices of ER+ breast cancer cells
by recruiting the actin-binding protein, moesin. Moesin resides at
the nexus of multiple pathways regulating cell attachment with the
extracellular matrix and with nearby cells, cell motility and
metastatic potential as well as cell survival. These functions are
directed by moesin though the modulation of actin cytoskeleton/
plasma membrane interactions.
Moesin activation by estrogen in breast cancer cells is linked to
the rapid and dynamic remodeling of the actin cytoskeleton and to
the formation of specialized cell membrane structures, such as
pseudopodia and ruffles, that are involved in the interaction with
the extracellular matrix and required for cell movement [6,22].
These actions are consistent with our previous observation of
improved wound healing due to enhanced endothelial cell
movement in the presence of estrogens, linked to the activation
of moesin [8], as well as with the recently reported activation of
cytoskeletal remodeling and cell migration by estrogens in
endometrial cancer [5].
Our findings also strengthen the concept that the nongenomic
signaling of estrogen receptor to ERM proteins and actin may be
of general relevance for the determination of cell movement.
Indeed, the actions described in this report occur within minutes
without the need of activating gene expression [23] and are
therefore dynamically shut off within 30 to 60 minutes. This
makes sense in light of the established requirement of multiple,
periodic, waves of actin remodeling and dynamic formation of
anchorage sites to the extracellular matrix in order to accomplish
cell movement [6,22].
In addition, loss of stress fibers is associated with cancer cell
transformation and metastasis [24]. Thus, the cytoskeletal
rearrangement induced by estrogen through moesin may in part
explain the carcinogenic actions of this steroid in estrogen-sensitive
breast cancers, along with the enhanced metastatic behavior of
such neoplasms in the presence of sex steroid hormones [4]. In
Figure 6. ERa signals to moesin via Ga13 and RhoA. A) T47-D cells were treated for 15 min with 10 nM E2 in the presence or absence of ICI
182,720 (ICI, 1 mM) and cells were stained with Abs vs. ERa (red staining) and Ga13 (green staining). Double staining, showing co-localization is
presented in the lower boxes in yellow. B) RhoA activity was assayed in T47-D treated for 15 min with 10 nM E2, E2 conjugated to BSA (E2-BSA, 10
nM), the ERa-preferential ligand PPT (10 nM) or the ERb-preferential agonist DPN (10 nM) in the presence or absence of ICI 182,720 (ICI, 1 mM) or PTX
(100 ng/ml). Active, GTP-bound, RhoA was precipitated with Rhotekin, and a western analysis for RhoA was then performed. C) Whole-cell extracts
were assayed for wild-type (moesin) or for Thr558-phosphorylated (P-moesin) moesin content after transfection with empty vector or with Ga13 or
RhoA constitutively active (Ga13 CA and RhoA CA) or dominant-negative (Ga13 DN and RhoA DN) constructs, in the presence or absence of E2 (10 nM;
15 min).
doi:10.1371/journal.pone.0002238.g006
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support of this, similar actions of estrogen linked to the regulation
of the ERM protein ezrin have been described in estrogen-
sensitive cancers [14,25].
ER- breast cancers, such as MDA-MB-468 cells, are not
sensitive to estrogen administration in terms of moesin activation
and cell migration. However, these cells display a basal hyper-
activation of moesin. In addition, a direct inhibitor of moesin
phosphorylation (ROCK inhibitor) is highly effective in reducing
MDA-MB-468 cell horizontal migration. These findings are
intriguing, as they suggest that sustained moesin activation by
ROCK might be an important player in the metastatic behavior of
ER- breast cancer cells. This fits with a previous report of a
prominent expression of moesin in ER- human breast tumors,
related to the tendency to metastasize [26].
The mechanistic basis that supports estrogen signaling to
moesin and the actin cytoskeleton is found in the recruitment of
the Ga13/RhoA/ROCK pathway by ERa. Similarly to what
previously found in human endothelial cells [8], estrogen-bound
ERa dynamically interacts with the G protein Ga13 and triggers its
activation. This leads to the recruitment of the small GTPase
RhoA and of its downstream effector, ROCK-2, which is
responsible for moesin phosphorylation. These signaling interme-
diates, including moesin, are all required for actin remodeling as
well as breast cancer cell migration and invasion. Interestingly,
ERb does not support the interaction with Ga13 nor it activates
moesin. Overall, this further establishes the nongenomic ERa/
Ga13/RhoA/ROCK/moesin signaling cascade as an important
controller of cell movement by estrogen in different cell types,
including cancer cells.
We also find that human breast cancers display a deranged
over-expression and over-activation of moesin respect to normal
breast tissues and/or benign fibroadenomas. Although our
observation is only descriptive and limited to a small sample of
patients, it is remarkable to find some variations in the sub-cellular
Figure 7. ERa recruits the Rho-associated kinase, ROCK-2. Breast cancer cells were treated for 15 min with 10 nM E2 in the presence or
absence of the ROCK-2 inhibitor, Y-27632 (Y; 10 mM), ICI 182,720 (ICI; 1 mM), or PTX (100 ng/ml). Wild-type moesin (moesin) or Thr558-phosphorylated
(P-moesin) moesin were assayed in T47-D (A) or MCF-7 (B) cell extracts. C) T47-D cancer cell protein extracts were immunoprecipitated with an Ab.
vs. ROCK-2 and the IPs were used to perform kinase assays using de-phosphorylated myelin basic protein (MBP) as a bait. The lower box shows
phosphorylation of MBP, the upper boxes show the re-blot of the membranes for ROCK-2, ERa or ERb. D and E) T47-D cell protein extracts were
immunoprecipitated with an Ab. vs. ERa (D) or ROCK-2 (E) and co-immunoprecipitation of ROCK-2 or ERa was assayed with western analysis. The
membranes were re-blotted for ERa or ROCK-2 to show equal input. F) Breast cancer cell protein extracts were immunoprecipitated with an Ab. vs.
ERa and the IPs were used to perform kinase assays using de-phosphorylated myelin basic protein (MBP) as a bait. The lower box shows
phosphorylation of MBP, the upper box shows the re-blot of the membrane for the immunoprecipitated protein.
doi:10.1371/journal.pone.0002238.g007
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localization of moesin in different cancer types. For instance, we
find a statistically significant loss of membrane localization of
moesin in ER2 vs. ER+ cancers, which calls for future work to
further characterize if the overall expression of this protein or its
sub-cellular positioning might be associated with different cancer
biology or behavior. This would be consistent with what is already
known for the parent ERM protein, ezrin. Ezrin has been found to
be over-expressed in invasive epithelial neoplasia, such as in
estrogen-sensitive endometrial [25] and breast carcinomas [13,27],
and in highly aggressive sarcomas as well [11,12], being related in
many of these studies to the presence of tumor metastasis.
In conclusion, the present results suggest that within the broader
range of actions of estrogen receptors, the rapid extra-nuclear
signaling to the actin cytoskeleton through the Ga13/RhoA/
ROCK/moesin cascade is relevant for the determination of
estrogen-dependent breast cancer cell movement and invasion that
are related to cancer metastasis. The characterization of these
actions increase our understanding of the effects of estrogens on
breast cancer progression and might be useful to develop new tools
to interfere with the ability to diffuse locally or at distant sites of
ER+ or ER2 breast carcinomas.
Materials and Methods
Cell cultures and treatments
The human breast carcinoma cell line T47-D, MCF-7 and
MDA-MB-468 were obtained from the American Type Culture
Collection. T47-D cells were grown in RPMI 1640 supplemented
with L-glutamine (2mM), 10% fetal bovine serum. MCF-7 were
cultured in minimal essential medium (MEM) with L-glutamine
(2mM) and 10% fetal bovine serum. MDA-MB-468 cells were
cultured in McCoy’s 5A medium with L-glutamine (2mM) and
10% fetal bovine serum. Before treatments, all breast cancer cells
lines were kept 24 hours in medium containing steroid-deprived
Figure 8. Actin remodeling by estrogen receptor requires Ga13, RhoA and ROCK-2. A) T47-D cells transiently transfected with either empty
vector or with plasmids encoding for constitutively active or dominant-negative Ga13 (Ga13 CA or Ga13 DN) or RhoA (RhoA CA or RhoA DN) were
treated for 15 min with 10 nM E2. Other cells also received a co-treatment with E2 (10 nM; 15 min) and the ROCK inhibitor Y-27632 (Y; 10 mM). Breast
cancer cell actin fibers were stained with phalloidin linked to Texas Red, and nuclei were counterstained with DAPI. B) shows the analytic results
obtained by using Leica QWin image analysis and processing software showing the mean thickness of the cell membrane as well as the intensity of
actin staining in the cytoplasm, membrane or extracellular compartment. The results are derived from the sampling of five areas of the cell
membrane of thirty different random cells. The areas of minimum and maximum cell membrane thickness were always included. The results are the
mean6SD of the measurements. * = p,0.05 vs. vehicle-transfected control. C) shows the changes of the amount of filamentous actin (F-actin, F)
content versus free globular-actin (G-actin, G) content in T47-D cells after treatment with E2 (10 nM) for 15 min, in the presence or absence of ER
antagonist ICI 182,720 (ICI; 1 mM), G protein inhibitor PTX (100 ng/ml) and ROCK-2 inhibitor Y-27632 (Y; 10 mM). Positive (Pos) and negative (Neg)
controls were set by adding F-actin enhancing solution (phalloidin, 1 mM) or F-actin depolymerization solution (10 mM cytochalasin-D) to the lysates,
respectively.
doi:10.1371/journal.pone.0002238.g008
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FBS. Before experiments investigating non-transcriptional effects,
cancer cells were kept in medium containing no FBS for 8 hours.
Whenever an inhibitor was used, the compound was added
30 minutes before starting the treatments. 17b-estradiol, 17b-
estradiol-BSA, tamoxifen, PTX, Y-27632, PD98059 and wort-
mannin were from Sigma-Aldrich (Saint-Louis, MO), ICI
182,780, PPT and DPN were obtained by Tocris Cookson
(Avonmouth, UK).
Immunoblottings
Cell lysates were separated by SDS-PAGE. Antibodies used
were: moesin (clone 38, Transduction Laboratories, Lexington,
KY), Thr558-P-moesin (sc-12895, Santa Cruz Biotechnology,
Santa Cruz, CA), ERa (TE111, NeoMarkers, Union City, CA),
ERb (N-19, Santa Cruz), ROCK-2 (C-20, Santa Cruz), Ga13 (A-
20, Santa Cruz), RhoA (26C4, Santa Cruz), wild-type ERK 1/2
(polyclonal, catalog no. 442704; Calbiochem Merck Biosciences,
GmbH, Darmstadt, Germany), Tyr204-P-ERK 1/2 (polyclonal,
catalog no. sc-7976; Santa Cruz Biotechnology, Santa Cruz, CA),
wild-type and Ser473-phosphorylated Akt (Upstate Biotechnology,
Inc., Lake Placid, NY). Primary and secondary Abs were
incubated with standard technique. Immunodetection was accom-
plished with enhanced chemiluminescence.
Cell immunofluorescence
T47-D cells were grown on coverslips and exposed to
treatments. Cells were fixed and permeabilized with methanol at
220uC for 10 min. Blocking was performed with 3% normal
serum for 20 min. Cells were incubated with antibodies against
human moesin (clone 38, Transduction Laboratories) or with
Texas Red-phalloidin (Sigma). The nuclei were counterstained
with or 49-6-diamidino-2-phenylindole (DAPI) (Sigma) and
mounted with Vectashield mounting medium (Vector Laborato-
ries, Burlingame, CA). Immunofluorescence was visualized using
Figure 9. Role of the G protein/ROCK/moesin pathway for ER+ breast cancer cell migration. Steroid-deprived, growth synchronized ER+
T47-D cells were exposed to 10 nM E2, in the presence or absence of the ER antagonist ICI 182,720 (ICI; 1 mM), of the G protein inhibitor PTX (100 ng/
ml), or of the ROCK-2 inhibitor, Y-27632 (Y; 10 mM) or of the selective estrogen receptor modulator (SERM) tamoxifen (TAM, 10 nM). In addition, some
T47-D cells were treated with 10 nM E2 in the presence or absence of transfection with sense (Sense; 2 mM) or antisense (AS; 2 mM) moesin
phosphorotioate oligonucleotides (PONs). Breast cancer cells were scraped from the culture dish and the mean migration distance of the cells from
the starting line was assayed after 48 h and expressed as mean6SD. Representative images are shown and the mean6SD of migration are shown in
the bar graphs. * = p,0.05 vs. E2.
doi:10.1371/journal.pone.0002238.g009
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an Olympus BX41 microscope and recorded with a high-
resolution DP70 Olympus digital camera. After conversion to
greyscale images, the cell membrane thickness and the gray levels
of the extracellular area, cell membrane as well as cytoplasm were
quantified using the Leica QWin image analysis and image
processing software (Leica Microsystems, Wetzlar, Germany).
Co-immunoprecipitation assays
T47-D cells were harvested in 100 mM Tris-HCl, pH 6.8, 4%
SDS, 20% glycerol, 1 mM Na3VO4, 1 mM NaF, and 1 mM
PMSF. Equal amounts of cell lysates were incubated with 1 mg of
precipitating Ab (ERa, ROCK-2 or Ga13) for 1 hour at 4uC under
gentle agitation. 25 mL of a 1:1 protein A-agarose slurry were
added, and the samples were rolled at 4uC for another hour. The
samples were then pelleted, washed, and resuspended in 50 mL of
26Laemmli buffer for immunoblotting.
Kinase assays
T47-D cells were harvested in 20 mM Tris-HCl, 10 mM
EDTA, 100 mM NaCl, 0.5% IGEPAL, 0.1 mg/mL PMSF. Equal
amounts of cell lysates were immunoprecipitated with an Ab vs.
ERa or ROCK-2. The IPs were washed three times with 20 mM
Tris-HCl,10 mM EDTA, 150 mM NaCl 0.1% IGEPAL, 0.1 mg/
mL PMSF. Two additional washes were performed in kinase assay
buffer (20 mM MOPS, 25 mM b-glycerophosphate, 5 mM
EGTA, 1 mM DTT) and the samples were therefore resuspended
in this buffer. 5 mg of de-phosphorylated myelin basic protein
(Upstate, Lake Placid, NY) together with 500 mM ATP and
75 mM MgCl2 were added to each sample and the reaction was
started putting the samples at 30uC for 20 min. The reaction was
stopped on ice and by resuspending the samples in Laemmli
Buffer. The samples were separated with SDS-PAGE and western
analysis was performed using an Ab recognizing Thr98-P-myelin
Basic Protein.
Figure 10. Role of the G protein/ROCK/moesin pathway for
ER2 breast cancer cell migration. ER2 MDA-MB-468 cells were
exposed to 10 nM E2, in the presence or absence of the ER antagonist
ICI 182,720 (ICI; 1 mM), of the G protein inhibitor PTX (100 ng/ml), or of
the ROCK-2 inhibitor, Y-27632 (Y; 10 mM) or of the selective estrogen
receptor modulator (SERM) tamoxifen (TAM, 10 nM). Breast cancer cells
were scraped from the culture dish and the mean migration distance of
the cells from the starting line was assayed after 48 h and expressed as
mean6SD. Representative images are shown and the mean6SD of
migration are shown in the bar graphs. * = p,0.05 vs. control.
doi:10.1371/journal.pone.0002238.g010
Figure 11. Role of the G protein/ROCK/moesin pathway for ER+ breast cancer cell invasion. Steroid-deprived, growth synchronized ER+
T47-D cells were exposed to 10 nM E2, or 10 nM E2-BSA conjugate in the presence or absence of the ER antagonist ICI 182,720 (ICI; 1 mM), of the G
protein inhibitor PTX (100 ng/ml), or of the ROCK-2 inhibitor, Y-27632 (Y; 10 mM) or of the selective estrogen receptor modulator (SERM) tamoxifen
(TAM, 10 nM). In addition, some T47-D cells were treated with 10 nM E2 in the presence or absence of transfection with sense (Sense; 2 mM) or
antisense (AS; 2 mM) moesin phosphorotioate oligonucleotides (PONs). Breast cancer cell invasion through matrigel was assayed by using invasion
chambers. Invading cells were counted in the central field of triplicate membranes. Invasion indexes and representative images in chambers with
matrigel are shown. * = p,0.05 vs. E2.
doi:10.1371/journal.pone.0002238.g011
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Rho Activity Assay
T47-D cells were treated and harvested in Mg2+ Lysis/Wash
Buffer (125 mM HEPES, pH 7.5, 750 mM NaCl, 5% Igepal CA-
630, 50 mM MgCl2, 5 mM EDTA and 10% glycerol). 1 mg of
proteins were used to pull-down active, GTP-bound, RhoA using
Rhotekin-GSH-agarose. The IPs were washed with Mg2+ Lysis/
Wash Buffer and therefore resuspended in 26 Laemmli buffer.
The IPs were separated on a denaturing acrylamide gel and
western analysis with an anti-RhoA Ab was performed.
G-actin/F-actin assay
The G-actin/F-actin assay kit was purchased from Cytoskeleton
Inc (# BK037, Denver, USA). This kit is used to determine
accurately the amount of filamentous actin (F-actin) content versus
free globular-actin (G-actin) content in a cell population. In brief,
confluent T47-D cells were harvested with lysis at 37uC and F-
actin stabilization buffer (50 mM PIPES, 50 mM KCl, 5 mM
MgCl2, 5 mM EGTA, 5% glycerol, 0.1% Nonidet P40, 0.1%
Triton X-100, 0.1% Tween 20, 0.1% 2-mercapto-ethanol,
0.001% antifoam C, 1 mM ATP) after treatments. Total protein
concentration was determined by standard method. Positive and
negative controls were set by adding F-actin enhancing solution
(phalloidin, 1 mM) or F-actin depolymerization solution (10 mM
cytochalasin-D) to the lysates, respectively. The lysates were
incubated at 37uC for 10 min, followed by a centrifuge at
2000 rpm for 5 min to pellet and discard unbroken cells.
Supernatant were centrifuged at 10,000 6 g for 1 h at 37uC.
After that, supernatant and pellet were both collected. Pellets were
resuspended to the same volume as the supernatant using ice cold
distilled water plus F-actin depolymerization solution (10 mM
cytochalasin-D) and put on ice for 1 h to dissociate F-actin.
According to the protein concentration previously measured,
equivalent volumes of supernatant and dissolved pellet were
loaded to run Western blot and G-actin/F-actin ratio was
quantified using a quantitative digital imaging system.
Transient transfections
T47-D cells were transfected with each plasmid (15 mg) using
the Lipofectin reagent (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. The transfected plasmids were: Ga13
Q226L, Ga13 Q226L/D294N, RhoA T19 and RhoA G14V, Ras
G12V and Ras S17N. All the inserts were cloned in pcDNA3.1+.
Figure 12. Moesin and P-moesin expression and sub-cellular localization in human normal breast tissue, benign fibroadenomas
and breast cancers. Histological sections (4 mm) from normal mammary glands, fibroadenomas or ER positive (ER+) breast cancers were used to
identify the expression and localization of moesin and P-moesin with immunochemistry. Wild-type moesin as well as Thr558-phosphorylated are
shown as brown labeling. The figure displays sample images from the tumors analyzed in Table 1. Particularly, The normal breast tissue comes from
Patient 2, the fibroadenomas is from patient 3. The breast cancer showing focal staining is that of patient 20, the cancer with membrane staining
comes from patient 13. The cancer showing mixed membrane/cytoplasmic staining is from patient 17. The ‘‘high expression’’ cancer is from patient
12.
doi:10.1371/journal.pone.0002238.g012
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Table 1.
NORMAL BREAST
MOESIN MEM MEM CYTO P-MOESIN MEM MEM CYTO
CYTO CYTO
1 INTENSE x INTENSE x
2 INTENSE x INTENSE x
3 INTENSE x INTENSE x
4 INTENSE x INTENSE x
5 INTENSE x INTENSE x
FIBROADENOMAS
MOESIN MEM MEM CYTO P-MOESIN MEM MEM/CITO CYTO
CYTO
6 INTENSE x INTENSE x
7 INTENSE x INTENSE x
8 INTENSE x INTENSE x
9 INTENSE x INTENSE x
10 INTENSE x INTENSE x
INV. DUCTAL CARCINOMAS
SIZE pNx ER% MOESIN MEM MEM CYTO P-MOESIN MEM MEM CYTO
CYTO CYTO
ER POS/LYMPH NODE POS
11 18 mm pN2a (7/16) 84% FOCAL x NEGATIVE
12 19 mm pN1m (1/8) 98% INTENSE x INTENSE x
13 15 mm pN1a (1/3) 98% INTENSE x INTENSE x
14 16 mm pN1a (2/24) 100% INTENSE x FOCAL x
15 16 mm pN3a (8/15) 95% INTENSE x FOCAL x
ER POS/LYMPH NODE NEG
16 14 mm 90% INTENSE x FOCAL x
17 15 mm 90% INTENSE x INTENSE x
18 10 mm 100% INTENSE x INTENSE x
19 15 mm 99% FOCAL x INTENSE x
20 18 mm 98% FOCAL x FOCAL x
ER NEG/LYMPH NODE POS
21 18 mm pN2a (7/16) 0% FOCAL x NEGATIVE
22 17 mm pN1m (1/17) 0% INTENSE x INTENSE x
23 11 mm pN1m (1/1) 0% INTENSE x INTENSE x
24 17 mm pN1a (2/19) 0% INTENSE x FOCAL x
25 13 mm pN3b (20/24) 0% INTENSE x FOCAL x
ER NEG/LYMPH NODE NEG
26 8 mm 0% INTENSE x NEGATIVE
27 16 mm 0% INTENSE x FOCAL x
28 13 mm 0% INTENSE x FOCAL x
29 15 mm 0% INTENSE x NEGATIVE
30 12 mm 0% FOCAL x INTENSE x
ALL ER NEG TUMORS VS. ALL ER POS TUMORS P,0.05 FOR ABSENCE OF MEMBRANE LOCALIZATION
Immunohistochemical analysis of moesin and P-moesin in normal breast tissue, benign breast disease and breast cancers. Negative indicates visible staining in less than
1% of the cells. Focal indicates staining in less than 30% cells. Intense indicates diffused staining throughout the tissue. Membrane (MEM) indicates staining exclusively
localized to the cell membrane in more than 90% of the cells; membrane/cytoplasm (MEM/CYTO) indicates staining both on the cell membrane as well as in the
cytoplasm in more than 90% of the cells; cytoplasm (CYTO) indicates staining of the cytoplasm without any evident membrane staining in more than 90% of the cells.
Staining patterns were independently adjudicated by two pathologists. SIZE indicates the diameter of the mammary node. pNx indicates the number of positive lymph
nodes. ER% indicates the percentage of tumor cells expressing ERs.
doi:10.1371/journal.pone.0002238.t001
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The constructs were obtained from the Guthrie cDNA Resource
Center (www.cdna.org). As control, parallel cells were transfected
with empty pcDNA3.1+ plasmid. Cells (60–70% confluent) were
treated 24 hours after transfection and cellular extracts were
prepared according to the experiments to be performed.
Gene silencing with RNA interference
Two synthetic small interfering RNA targeting estrogen
receptor a (siRNA SMARTpool ESR1, Dharmacon, USA) were
used at the final concentration of 100 nM to silence ERa
according to the manufacturer’s instructions. T47-D breast cancer
cells were treated 60 hours after siRNA transfection. The efficacy
of gene silencing was checked with western analysis and found to
be optimal at 60 hours.
Moesin silencing with antisense oligonucleotides
Validated antisense phosphorotioate oligonucleotides (S-modi-
fied) (PONs) complementary to the 1-15 position of the human
moesin gene coding region [28] were obtained. The sequence was
59-TACGGGTTTTGCTAG-39 for moesin antisense PON. The
complementary sense PON was used as control (59-CTAG-
CAAAACCCGTA-39). PONs transfections were performed on
sub-confluent T47-D breast cancer cells. PONs were resuspended
in serum-free medium with 2% Lipofectin (Invitrogen) and added
to the culture medium every 12 hours at the final concentration of
4 mM. Every 24 hours T47-D cells were washed and fresh
medium supplemented with 4 mM of PONs was added. Moesin
silencing was assessed through protein analysis up to 72 hours
following transfection.
Cell migration assay
Cell migration was assayed with razor scrape assays. Briefly, a
razor blade was pressed through the confluent T47-D breast
cancer cell monolayer into the plastic plate to mark the starting
line. T47-D cells were swept away on one side of that line. Cells
were washed, and 2.0 mL of DMEM containing steroid-deprived
FBS and gelatin (1 mg/mL) were added. Cytosine b-D-arabino-
furanoside hydrochloride (Sigma) (10 mM), a selective inhibitor of
DNA synthesis which does not inhibit RNA synthesis was used 1 h
before the test substance was added to prevent cell proliferation.
Absence of cell proliferation and viability of the cells were checked
in preliminary experiments with MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) tests. Migration was moni-
tored for 48 hours. Every 12 h fresh medium and treatment were
replaced. Cells were digitally imaged and migration distance was
measured by using phase-contrast microscopy.
Cell invasion assay
Cell invasion were assayed using the BD BioCoatTM Growth
Factor Reduced (GFR) MatrigelTM Invasion Chamber (BD
Bioscience, USA). In brief, after rehydrating the GFR Matrigel
inserts, the test substance was added to the wells. An equal number
of Control Inserts (no GFR Matrigel coating) were prepared as
control. 0.5 mL of T47-D cell suspension (2.56104 cells/mL) were
added to the inside of the inserts. The chambers were incubated
for 24 h at 37uC, 5% CO2 atmosphere. After incubation, the non-
invading cells were removed from the upper surface of the
membrane using cotton tipped swabs. Then the cells on the lower
surface of the membrane were stained with Diff-Quick stain. The
invading cells were observed and photographed under the
microscope at 1006magnification. Cells were counted in the
central field of triplicate membranes. The invasion index was
calculated as the % invasion test cell/% invasion control cell.
Tissue specimens
Wild-type and phosphorylated-moesin expression was investi-
gated in 20 ductal invasive breast adenocarcinomas, stage pT1c.
Five of these were ER+/N+, 5 were ER+/N2, 5 were ER+/N+ and
5 were ER2/N2. In addition, we also evaluated moesin and P-
moesin in benign breast fibroadenomas (n = 5) as well as in normal
breast tissue (n = 5). Samples were collected according to
conventional histopathological diagnostic protocols and were fixed
in 10% buffered formalin, embedded in paraffin, and stained with
hematoxylin-eosin. Histological diagnosis and grading were
performed according the World Health Organization Classification of
Tumors (2002), and staging was determined according to the TNM
system.
Immunohistochemistry
Histological sections of 4 mm were mounted on silanized slides
and allowed to dry for 1 h at room temperature (RT), followed by
1 h incubation in an oven at 60uC. Briefly, after deparaffination
and rehydration, epitope retrieval was performed by immersing
slides in DAKO Epitope Retrival Solution (0.01 M citrate buffer,
pH 6.0) in a water bath at 98uC for 40 minutes followed by a
20 minutes cool-down period at RT. The working dilution for the
anti-human moesin monoclonal antibody (clone 38; BD Biosci-
ences) was 1:50. P-moesin was evaluated with anti-P-moesin goat
polyclonal antibody (Santa Cruz) at 1:50 dilution. The sections
were incubated with primary antibodies for 1 hour at RT. The
DAKO EnVision detection system kit was employed to detect
moesin, instead for P-moesin the DAKO LSAB+ was used.
Moesin and P-moesin expression were scored as positive when
there was cytoplasmic, membrane or both cytoplasmic and
membrane immunostaining. Staining scores were established
semi-quantitatively from the percentage of Moesin+ and P-moesin+
cells and the staining intensity. Tumors were graded as negative
(,1% positive cells), focal (low intensity, with $1% to ,30%
positive cells), intense (moderate or high intensity with diffused
positive cells). Staining patterns were independently adjudicated
by two pathologists.
Statistical analysis
All values are expressed as mean6SD. Statistical differences
between mean values were determined by ANOVA, followed by
the Fisher’s protected least significance difference (PLSD).
The x2 test, Fisher’s exact test were used to evaluate the
significance of the expression pattern of moesin and p-moesin and
the clinical and pathological parameters with version 12 of the
SPSS software package (SPSS Inc, IL, USA). A value of P,0.05
was considered significant.
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